Global drugmakers may face more competition in Russian anti-cancer drugs market

2 February 2021

The level of competition in the Russian anti-cancer drugs market is getting tougher, which is mainly due to the launch of new biosimilar drugs by domestic players and expansion of the local ranges.

For example, the local drugmaker Ozon Pharmaceuticals is ready to begin commercial production of its own generic of trastuzumab, which is one of the best-selling breast cancer drugs in Russia and the original of which under the Herceptin brand is currently produced by Swiss giant Roche (ROG: SIX).

According to Ozon, it has recently entered the final phase of testing of its drug, hoping to take part in public procurements with its drug already in the short term.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK